Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™

This is an early regulatory milestone, not a near-term investment catalyst.

What the company is saying

Vivos Inc. is positioning itself as a pioneering cancer therapy company, emphasizing its recent FDA approval to begin a first-in-human feasibility study for its RadioGel® product. The company wants investors to believe that this regulatory green light is a major step toward commercializing a novel, targeted cancer treatment. The announcement highlights the FDA's approval of their Investigational Device Exemption (IDE) application, the planned study at Mayo Clinic, and the use of RadioGel® in patients with non-resectable papillary thyroid carcinoma. Vivos frames its narrative around years of successful preclinical animal studies, asserting that these results demonstrate both safety and effectiveness, though no human data is yet available. The language is aspirational and forward-looking, with repeated references to multi-track strategies, commercial adoption, and international licensing opportunities for related platforms like IsoPet® and PrecisionGel™. The announcement is promotional in tone, projecting confidence and excitement about the partnership with Mayo Clinic and the potential to address unmet medical needs. However, it buries the fact that the human study is only just beginning, will initially enroll just five patients, and provides no evidence of commercial traction or financial performance. Notable individuals named include Brad Weeks (President), Mike Korenko (CEO), and Dr. Darrell R. Fisher (nuclear medicine physicist), all of whom are directly affiliated with Vivos or its technical partners, rather than representing external institutional validation. This narrative fits a classic early-stage biotech investor relations strategy: spotlighting regulatory milestones and scientific promise to build anticipation, while deferring hard financial or commercial evidence to the future.

What the data suggests

The only concrete numerical data disclosed is that the initial human feasibility study will enroll five patients. There are no financial figures, revenue numbers, or period-over-period metrics provided, making it impossible to assess the company's financial trajectory or operational scale. The announcement does not include any data on cash position, burn rate, or funding runway, nor does it disclose any commercial agreements, sales, or licensing revenue. The gap between the company's claims and the evidence is significant: while the company asserts years of successful preclinical work and strategic commercial ambitions, it provides no supporting data, published results, or third-party validation. There is no indication that prior targets or guidance have been met, as no such targets are disclosed. The quality of financial disclosure is extremely poor, with no transparency on key metrics that would allow an investor to evaluate risk or upside. An independent analyst, looking only at the numbers, would conclude that this is a very early-stage clinical milestone with no immediate financial implications, and that the company remains in a pre-revenue or pre-commercial phase. The lack of operational or financial data means that the announcement is not actionable from a quantitative investment perspective.

Analysis

The announcement is upbeat, highlighting FDA approval for a feasibility study and referencing years of preclinical work. However, nearly all key claims are forward-looking: the study has not yet begun, only five patients are expected to enroll initially, and there is no evidence of commercial adoption or monetization. The only realised milestone is the FDA's approval to start a small-scale feasibility study, which is an early-stage regulatory step rather than a commercial or financial inflection point. No financial, revenue, or profitability data is disclosed, and there are no signed commercial agreements or evidence of immediate earnings impact. The language inflates the signal by referencing broad strategic ambitions and preclinical results without providing supporting data or quantifiable progress in humans. The gap between narrative and evidence is significant: the company is at the very start of human clinical testing, with all commercial and financial benefits long-dated and highly uncertain.

Risk flags

• ●The company is at the very start of human clinical testing, with only a five-patient feasibility study approved. This means all commercial and financial benefits are speculative and years away, exposing investors to high clinical and regulatory risk.
• ●No financial data is disclosed in the announcement—no revenue, cash position, burn rate, or funding status. This lack of transparency makes it impossible to assess the company's financial health or its ability to fund ongoing operations.
• ●The announcement relies heavily on preclinical animal data to support claims of safety and effectiveness, but provides no human data or published results. Animal studies do not guarantee human efficacy or regulatory approval, so the translational risk is significant.
• ●All major claims about commercial adoption, international licensing, and monetization are forward-looking and unsupported by contracts, revenue, or third-party validation. This pattern of aspirational language without evidence is a classic red flag for hype.
• ●The feasibility study is being conducted at a single site (Mayo Clinic) with a very small initial cohort, which limits the generalizability and statistical power of any results. If enrollment is slow or results are inconclusive, the development timeline could be further extended.
• ●There is no mention of partnerships with major pharmaceutical companies, institutional investors, or external validation beyond the Mayo Clinic study site. The absence of external financial or strategic backing increases the risk that the company will struggle to scale or commercialize its technology.
• ●The company references a 'multi-track strategy' and multiple product platforms, but provides no operational details, milestones, or metrics for any of these initiatives. This lack of specificity makes it difficult for investors to track progress or hold management accountable.
• ●The announcement's tone is highly promotional, emphasizing potential and vision over realized results. Investors should be wary of announcements that inflate early regulatory steps into major breakthroughs without supporting data.

Bottom line

For investors, this announcement signals that Vivos Inc. has cleared an early regulatory hurdle by receiving FDA approval to begin a small-scale, first-in-human feasibility study for its RadioGel® cancer therapy. However, the practical impact is limited: the study has not yet started, will enroll only five patients, and no human efficacy or safety data is available. The company's narrative is built on preclinical animal studies and broad strategic ambitions, but there is no evidence of commercial traction, revenue, or financial stability. No external institutional investors or partners are named, and all notable individuals are insiders, so there is no independent validation of the company's prospects. To change this assessment, the company would need to disclose actual patient enrollment, interim clinical results, signed commercial agreements, or meaningful financial data. Investors should watch for concrete milestones in the next reporting period: study initiation, patient dosing, interim safety/efficacy results, and any evidence of commercial or licensing progress. At this stage, the announcement is not actionable for investment—there is no near-term catalyst, and the risk/reward profile is highly speculative. The most important takeaway is that this is a very early-stage clinical development story, not a signal of imminent commercial or financial upside.

Announcement summary

(OTCQB: RDGL) Vivos Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Feasibility Investigational Device Exemption (IDE) application. This approval allows the company to begin the US based first-in-human feasibility study using RadioGel ®, an innovative yttrium-90-based injectable hydrogel for the targeted treatment of cancerous tumors. The study will be conducted at Mayo Clinic in Jacksonville, FL and will evaluate the safety and feasibility of RadioGel ® in patients with non-resectable papillary thyroid carcinoma. The protocol is expected to initially enroll five patients. Over many years, preclinical studies in veterinary patients (cats, dogs, and horses) and laboratory animals (rabbits) demonstrated the safety and effectiveness of Yttrium-90 RadioGel ® precision radionuclide therapy (PRnT) in cancer treatment. Across multiple studies, histopathology confirmed no radiation-associated adverse effects in any normal organs or tissues. Vivos continues to advance its multi-track strategy by expanding commercial adoption of IsoPet ® for veterinary oncology and pursuing international licensing and monetization opportunities for the PrecisionGel ™ platform.

Disagree with this article?